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BRIEF COMMUNICATION
Patent ductus arteriosus (PDA) in low-birth-weight
premature infants that causes large left-to-right
shunts is associated with congestive heart failure,
bronchopulmonary dysplasia (BPD), necrotizing
enterocolitis (NEC), intracranial hemorrhage, and
death.1–4 For most preterm infants with PDA, the
hemodynamic effects are not immediately life-
threatening and can be controlled medically with-
out interventional ductus closure. Small preterm
infants weighing < 1500 g at birth frequently have
a prolonged course of ductus shunting, and char-
acteristically require days or weeks of mechanical
ventilation. Surgical ligation of the PDA in these
infants improves lung compliance, decreases 
duration of assisted ventilation, and increases
nutritional utilization.5,6
Although PDA ligation is a definitive treat-
ment, the optimal time to ligation in very-low-
birth-weight (< 1500 g) premature infants remains
controversial. Early surgical ligation has been ad-
vocated as the optimal therapy for PDA because
it ensures definitive ductal closure with minimal
morbidity and mortality.2,7 However, some studies
have shown that PDA closure does not significantly
influence outcome.8–10
We performed a retrospective study to com-
pare the efficacy and side effects between early
and late ligation of symptomatic PDA.
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Optimal time to surgical ligation of patent ductus arteriosus (PDA) in very-low-birth-weight (< 1500 g)
premature infants remains an area of controversy. We compared the outcomes of early or late ligation of
medical refractory PDA in very-low-birth-weight premature infants. Fifty-six infants underwent surgical
closure of PDA after failure of or having contraindications to medical treatment. Thirteen infants were 
in the early ligation (≤ 14 days) and 43 in the late ligation (> 14 days) groups. Basic clinical features, major
morbidity of prematurity and mortality were compared. Clinical features and major outcomes were 
similar. The early ligation group had earlier onset of symptomatic PDA (5.7 ± 1.6 days vs. 8.1 ± 3.6 days,
p = 0.024), and fewer days of total parenteral nutrition (TPN) (39.6 ± 13.9 days vs. 60.4 ± 31.4 days,
p = 0.025) and ventilator use (11.1 ± 6.7 days vs. 18.6 ± 10.5 days, p = 0.019). Early ligation of medical 
refractory PDA in very-low-birth-weight premature infants improves enteral feeding tolerance and reduces
TPN and ventilator use, but long-term benefits need further investigation. [J Formos Med Assoc 2009;
108(1):72–77]
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Methods
Patients
We retrospectively reviewed the charts of all pre-
mature infants with birth weight < 1500 g admit-
ted between 1 January 2001 and 31 December 2003
to the neonatal intensive care unit (NICU) at 
the Children’s Hospital of New York-Presbyterian
(CHONY). The Institutional Review Board for
human subject research approved the chart review.
We excluded patients transferred from other hos-
pitals, and those with major congenital anomalies
and complex congenital heart disease (CHD).
Inclusion criteria
Symptomatic PDA was diagnosed definitively by
bedside Doppler ultrasonography. The indications
for testing were based on clinical factors includ-
ing a murmur, bounding pulse, hyperdynamic
precordium, tachycardia and a need for increased
ventilatory support associated with radiographic
evidence of cardiomegaly or pulmonary conges-
tion. When PDA was diagnosed, a short trial of in-
domethacin therapy was instituted. The protocol
for indomethacin treatment was the usual 0.2 mg/
kg intravenously, every 12–24 hours for three
doses, as a full course, if there was no contraindi-
cation. Contraindications for indomethacin treat-
ment included: serum creatinine > 1.7 mg/dL,
active bleeding, sepsis, NEC, or oliguria. If the
PDA remained open according to clinical or echo-
cardiographic evaluation after the first course of
indomethacin, a second course was given if there
were no contraindications. The criteria for PDA
ligation included a hemodynamically significant
PDA by echocardiography, ventilator dependence,
and failure of indomethacin treatment or a con-
traindication to its use. Contraindications for
PDA ligation included severe pulmonary hyper-
tension with predominant right-to-left or bidirec-
tional shunt, life-threatening infection, and septic
shock. Surgical ligation was performed in the
NICU operating room under general anesthesia.
The duct was approached through a left lateral
thoracotomy, and suture ligation or hemoclipping
was performed.
Procedure
The premature infants with symptomatic PDA
refractory to or contraindicated for medical clo-
sure, who underwent surgical ligation, were our
target population. They were divided into two
groups: early ligation (EL; age ≤ 14 days) and late
ligation (LL; age > 14 days). The groups were com-
pared with regard to gestational age, birth weight,
Apgar score, antenatal steroids, respiratory dis-
tress syndrome (RDS), surfactant use, mean air-
way pressure, first day of symptomatic PDA, and
mean age at surgery (Table 1). Outcome assessed
included BPD (defined as need for oxygen or 
Table 1. Population characteristics*
EL (n = 13) LL (n = 43) p
Gestational age (wk) 24.8 ± 1.1 25.3 ± 1.6 0.298
Body weight (g) 694 ± 199 714 ± 183 0.736
Male gender 7 (53.8) 22 (51.2) 0.862
Apgar at 1 min 4.33 ± 2.8 4.83 ± 2.1 0.490
Apgar at 5 min 7.33 ± 1.2 7.23 ± 1.2 0.793
Antenatal steroid 7 (53.8) 27 (62.8) 0.977
Respiratory distress syndrome 10 (76.9) 39 (90.7) 0.912
Surfactant use 4 (30.7) 16 (37.2) 0.987
Airway pressure (cmH2O) 8.4 ± 2.1 8.7 ± 2.4 0.687
First day of symptomatic PDA 5.7 ± 1.6 8.1 ± 3.6 0.024†
Age at surgery 11.2 ± 2.5 20.3 ± 4.3 0.001†
*Data presented as mean ± standard deviation or n (%); †significant difference. EL = early ligation (age ≤ 14 d); LL = late ligation 
(age > 14 d); PDA = patent ductus arteriosus.
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respiratory support at 36 weeks of postconcep-
tual age), grade III and IV intraventricular hem-
orrhage (IVH), stage 3 and 4 retinopathy of
prematurity (ROP), NEC, acute renal failure (ARF;
creatinine > 1.7 mg/dL), pneumothorax and mor-
tality (Table 2). Nasal continuous positive airway
pressure (CPAP), ventilator use, duration of total
parenteral nutrition (TPN), and length of hospital
stay were compared.
Statistical analysis
Statistical analysis was performed using a two-
tailed Student’s t test for continuous variables and
Fisher’s two-tailed exact test for dichotomous
variables. Continuous variables were reported as
mean ± standard deviation. A value of p < 0.05 was
considered significant.
Results
A total of 448 infants with < 1500 g body weight
were born at CHONY and admitted to the NICU
between 1 January 2001 and 31 December 2003.
Thirty-two infants who had major congenital
anomalies or complex CHD were excluded. A
total of 167 cases (40.1%) developed symptomatic
PDA, and 111 infants (66.5%) were successfully
closed by medical treatment, which was confirmed
by Doppler ultrasonography. A total of 56 cases
(33.5%) underwent surgical ligation of sympto-
matic PDA, and were divided into the EL (age
≤ 14 days, n = 13) and LL (age > 14 days, n = 43)
groups (Figure 1). The gestational age of the study
infants was 23–31 weeks and birth weight was
430–1310 g. There were no significant differences
between the groups for gestational age, birth
weight, APGAR score, antenatal steroid use, RDS,
surfactant use, and mean airway pressure. The sig-
nificant differences were first days of symptomatic
PDA and mean age at surgery (Table 1). The two
groups were clinically similar and cared for in
the same fashion.
Major morbidity and mortality are summa-
rized in Table 2. Patient outcomes were similar.
BPD requiring oxygen therapy beyond 36 weeks
postconceptual age occurred in two surviving in-
fants in the EL group and 10 in the LL group
(p = 1.000). NEC was noted in one infant in the
EL group and in eight patients in the LL group,
although this was not a significant difference
(p = 0.670). Two infants in the EL and seven in the
LL group died, but the difference was not signifi-
cant (p = 1.00). Other morbidities that were com-
mon in premature infants, including ARF, grade III
and IV IVH, stage 3 and 4 ROP, and pneumotho-
rax, did not differ significantly between the two
groups.
The EL group received nasal CPAP for 59.4 ±
25.6 days, similar to the 63.2 ± 28.4 days in the
LL group (p = 0.668). The EL group received me-
chanical ventilation for 11.1 ± 6.7 days, which was
significantly shorter than the 18.6 ± 10.5 days in
the LL group (p = 0.019). The EL group received
TPN for 39.6 ± 13.9 days, which was significantly
shorter than the 60.4 ± 31.4 days in the LL group
(p = 0.025). The mean length of hospital stay in
the EL group was 92.3 ± 47.1 days, which did not
Table 2. Morbidities and mortality*
EL (n = 13) LL (n = 43) p†
Necrotizing enterocolitis 1 (7.7) 8 (18.6) 0.670
Bronchopulmonary dysplasia 2 (15.4) 10 (23.3) 1.000
IVH grade III + IV 2 (15.4) 11 (25.6) 0.718
Acute renal failure 2 (15.4) 6 (14.0) 1.000
ROP stage 3 and 4 3 (23.1) 13 (30.2) 1.000
Pneumothorax 2 (15.4) 3 (6.9) 0.589
Deaths 2 (15.4) 7 (16.3) 1.000
*Data presented as n (%); †Fisher’s exact test. EL = early ligation (age ≤ 14 d); LL = late ligation (age > 14 d); IVH = intraventricular
hemorrhage; ROP = retinopathy of prematurity.
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differ significantly from the 101.0 ± 33.4 days in
the LL group (p = 0.461) (Figure 2).
Discussion
Our results indicated that the days of ventilator
use and duration of TPN use were significantly
shorter in premature infants with early surgical
ligation (age ≤ 14 days) of symptomatic PDA that
was refractory to medical treatment. We found
no evidence that delayed duct closure was associ-
ated with BPD, NEC, IVH, ARF, ROP, length of
hospital stay, or death.
The patency of the ductus arteriosus makes a
“diastolic steal” of blood flow from the abdomi-
nal organs to the pulmonary artery and causes
impaired intestinal blood flow.11 Cassady et al con-
firmed that impaired intestinal blood flow may
cause feeding intolerance and NEC in premature
infants, and that early prophylactic ligation of
PDA in extremely-low-birth-weight infants re-
duces the incidence of NEC.12 This can explain
why early ligation of PDA led to a shorter dura-
tion of TPN use and was able to meet most of the
patients’ nutritional needs at an earlier age, as well
as sparing certain serious complications of TPN.
Jaillard et al have also shown that early surgical
closure of the ductus arteriosus (< 3 weeks old) is
associated with a shorter delay in full oral feeding
and improved body growth, when compared with
late surgical closure (> 3 weeks old).5 NEC oc-
curred in one of 13 infants in our EL group, but
was noted in eight of 43 infants in the LL group.
Early ligation of symptomatic PDA seemed to have
a trend towards reducing NEC, but did not make
a significant difference in our study.
We found that infants in the EL group had
fewer days of mechanical ventilation (11.1 ± 6.7
days vs. 18.6 ± 10.5 days in LL, p = 0.019), but BPD
incidence did not differ. Early ligation of PDA 
VLBW (BW ≤ 1500 g) infants (n = 448)
Doppler ultrasonography diagnosis of
symptomatic PDA (n = 167)
EL group
≤ 14 d (n = 13)
LL group
> 14 d (n = 43)
Medical closure group (n = 111)
• Closure in 1st course of indomethacin
 treatment (n = 61)
• Closure in 2nd course of indomethacin
 treatment  (n = 50)
Surgical closure group (n = 56)
• Failure to close after indomethacin
 treatment (n = 48)
• Contraindication to indomethacin
 treatment (n = 8)
Not enrolled (n = 32)
• Major congenital
 anomaly (n = 15)
• Complex congenital heart
 disease (n = 17)
Figure 1. Flow diagram of very-low-birth-weight (VLBW) infants who were treated for symptomatic patent ductus 
arteriosus (PDA) and assigned to early ligation (EL) and late ligation (LL) groups.
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Figure 2. Clinical outcome. N-CPAP = nasal continuous
positive airway pressure; TPN = total parenteral nutrition;
LOS = length of stay.
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improves pulmonary edema in premature in-
fants,13,14 thus we can wean infants off ventilation
earlier, but many factors are considered to con-
tribute to the occurrence of BPD in premature 
infants. The evidence of PDA and its closure on
respiratory status in premature neonates is not
clear. Gerhardt and Bancalari13 and Szymankiewicz
et al14 reported improved lung function after sur-
gical closure of PDA. Farstad and Bratlid,15 how-
ever, found no difference in compliance with ductal
closure in infants with RDS. We did not find in
our series or any published report that early liga-
tion of PDA reduced BPD in premature infants.
Yeh and associates have suggested that the devel-
opment of BPD is linked to the severity of RDS and
the high inspired oxygen concentrations deliv-
ered within 4 hours of age.16 For this reason, they
proposed that any therapeutic regimen should be
instituted very early to have any effect on reducing
the development of BPD.
The results of this study provide a rational so-
lution to an important management dilemma.
Even though CHF and pulmonary edema is satis-
factorily controlled, we believe that the infant
with symptomatic PDA who has failed treatment
with indomethacin will benefit from early surgi-
cal closure of the ductus. The incidence of surgical
complications in the present study was minimal
and consistent with the 4–10% morbidity re-
ported in the literature.11,17 Any infants with pro-
gressive, uncontrolled CHF or pulmonary edema
should undergo immediate ductus closure as a
lifesaving measure, unless the shunting in the
ductus is right-to-left or bidirectional.
Our study was not a randomized controlled
trial. The number of subjects was limited by the
fact that the occurrence of symptomatic PDA in
very-low-birth-weight infants refractory to med-
ical closure was infrequent, and patients transferred
from or referred to other hospitals were excluded
because of follow-up difficulties and possible dif-
ferences in treatment strategy. The long-term out-
comes of PDA ligation were not followed in our
study. Kabra et al reported that surgical PDA clo-
sure was a risk factor for neurosensory impairment
at 18 months in children who were enrolled in the
Trial of Indomethacin Prophylaxis in Preterms.18 Con-
trolled trials with long-term follow-up are urgently
needed to better delineate the role of surgical
closure of PDA in the care of premature infants.
In conclusion, early ligation of medical re-
fractory PDA in very-low-birth-weight premature
infants improves enteral feeding tolerance and
reduces TPN and ventilator use, but it does not
improve the major outcomes of premature in-
fants. The long-term benefits or harms need to
be further evaluated.
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